We aim to be a global healthcare leader, going beyond the Korean market
We aim to be a global healthcare leader, going beyond the Korean market

Growth to a global healthcare group

Present ~ 2020
Obtained the 1st place in terms of the customers’ most reliable vitamin for ‘Impactamin’
‘Nuceiva’ (Korean product name: Nabota), a botulinum toxin, launched in Italy
Issued its first sustainable management report
Executed an agreement for ‘Fexuclue’ with ‘Cooper Pharma,’ a Moroccan pharmaceuticals company
Obtained product approval in Korea for ‘Envlomet,’ a diabetes combination drug
Launched a new drug ‘Envlo Tab,’ the first made-in-Korea SGLT-2 inhibitor for diabetes treatment in Korea
Won the Grand Prize in the field of botulinum toxin for the 2023 Korea Representative Brand with ‘Nabota’ for two consecutive years
Won the ‘Customers’ Mostly Recommended Brand’ with ‘Ursa’ for two consecutive years
Signed a joint research contract with Oncorus in US for new mRNA anticancer drugs
Obtained approval for botulinum toxin ‘Nuceiva’ (Korean product name: Nabota) in Australia
Signed a contract with CS Pharmaceuticals to export the technology of Bersiporocin, a new drug for pulmonary fibrosis, to East Asian culture sphere
Obtained product approval in Ecuador for the first time in Central and South America for ‘Fexuclue’, a new drug for gastroesophageal reflux disease
Obtained product approval in Singapore for ‘Nabota’, a botulinum toxin
’Envlo’, a new drug for diabetes treatment, won the Grand Prize at the Korea New Drug Award
Selected as ‘South Korea’s 100 Best Companies to Work For’
‘Envlo’, a new diabetes treatment drug, signed a contract with M8 Pharmaceuticals for export to Brazil and Mexico
‘Nuceiva’ (Korean product name: Nabota), a botulinum toxin, launched in Germany and Austria
Acquired product approval in Chile for gastroesophageal reflux disease drug Fexuclue
Company certified as ‘a good company to work for’ and selected as ‘the most familyfriendly company’ in 2022
Company received the silver prize in the smart factory category of the national quality team competition
‘Envlo’, a new diabetes treatment drug as a new diabetic drug approved in Korea
DWN12088, a new drug for idiopathic pulmonary fibrosis, selected for a national new drug development project
a new drug for gastroesophageal reflux disease ‘Fexuclue’, approved by Food and Drug Administration (FDA) of the Philippines
Launched botulinum toxin ‘Nuceiva’(Korean product name: Nabota) in the UK
Approved a phase 1 clinical trial of DWP213388, a new drug candidate being developed for autoimmune diseases from the U.S. FDA
Acquired permission for cell processing facility for CDMO business
Received fasttrack designation from the U.S. FDA for the first time as a new drug for idiopathic pulmonary fibrosis in Korea
Launched ‘Fexuclue Tablet’, a new drug for gastroesophageal reflux disease in Korea
Declared the 2030 Global No. 1 vision for drug formulation technology
Acquired sales license of Botulinum toxin ‘Nabota’ in Saudi Arabia and Ukraine
Succeeded in Phase 3 clinical trial for Botulinum toxin ‘Nabota’ for the first time in the world to improve square jaw
Approved Phase 3 Clinical Trial of Enavogliflozin, a new diabetes drug in China
Won the grand prize for ‘Fexuclue’ in the new drug development sector of the Korea New Drug Development Awards
Yoon Jae-chun appointed vice chairman of Daewoong Pharmaceutical Co., Ltd. Daewoong to be led by joint representative directors Jeon Seung-ho and Lee Chang-jae
Achieved record sales of 1.153 trillion won in 2021
Application filed for permission of sale of botulinum toxin 'Nabota' in China
Contracts signed for Fexuprazan, a new drug for gastroesophageal reflux disease, for market entry in China, the United States, four countries in Central and South America, and six countries in the Middle East
Acquired domestic sales approval of Fexuclue for gastroesophageal reflux disease, as the 34th domestically developed drug
V-Olet, an injection to reduce excessive jaw fat has been released
Rebamipide-based gastritis treatment 'Mucotra SR Tab. 150mg' has been released
'DWN12088', a new drug for fibrosis, has been additionally designated a rare drug by FDA
Received government funding for manufacturing equipment of COVID-19 treatment drug DWRX2003
Obtained approval for advanced biologics manufacturing; company begins engaging in the CDMO business
Selected No. 10 Best Place to Work in Asia
Received the '2021 Korea PR Grand Prize' for public and public interest campaigns
Received the Grand Prize for Trustworthy Management for '100 Best Places to Work in Korea 2020'
Signed a clinical MOU with the Indonesian government for COVID-19 treatment
Provided practical training program for selected Indonesian pharmaceutical talents
Developed COVID-19 treatment and selected for a government-sponsored project
Concluded agreements with Seasun Biomaterials and Genomictree to supply COVID-19 test kits
Selected as a company with the highest grade in work innovation (Grade SS)
Obtained “Best HRD” in 2020, a certification for human resources development
Obtained “KOSHA-MS,” a certification for the safety and health management system
Novel diabetes drug Enavogliflozin designated for expedited review for the first time in Korea and conducted a phase 3 clinical trial
Registered as a bio-pharmaceutical accelerator, and sign an MOU with Gyeongsangnam-do, Gimhae, and Inje University
Established iN Therapeutics, a drug discovery company (spun off from Daewoong Pharmaceutical)
AEON Biopharma, a partner company in the botulinum toxin market for advanced countries, approved for a phase 2 clinical trial in the US
Selected as a company to be supported by the Ministry of Food and Drug Safety (MDFS) for Quality by Design (QbD)
Independently developed botulinum toxin Nabota obtained marketing authorization in Taiwan and Brazil
Obtained halal certification for Easyef Topical Solution and Epodion through Daewoong Infion, a joint venture in Indonesia
Concluded agreements with Mexico and Brazil to export the next-gen gastroesophageal reflux disease drug Fexuprazan
Established AffyXell Therapeutics, a joint venture specializing in cellular therapeutics, with the British biotech company Avacta

'Through open collaboration
Reinforcing world-class competitiveness'

Daewoong Pharmaceutical alone surpassed KRW 1 trillion in sales volume for the first time
Acquired International Quality Management System Standard ISO9001
Completed phase 3 clinical tests for the next-generation gastroesophageal reflux disease medicine, ‘Fexuprazan’
Received ‘Best 100 Companies to Work at in Korea’ award
Received Minister of Employment and Labor Award at the ‘2019 Company Togetherness Awards & CSR Film Festival’
Government Innovative Pharmaceutical Company award
Launched proprietarily developed botulinum toxin ‘Nuceiva’ (Canadian product name) in Canada
Received sales permit in Europe for proprietarily developed botulinum toxin ‘Nuceiva’ (European product name)
Acquired International Environmental Safety and Health Certification 'ISO 14001', 'ISO 45001'
US FDA designated new pulmonary fibrosis drug DWN12088 as rare drug
URSA 300mg’, acquired indication for ‘prevention of gallstone after stomach incision’ for the first time in the world
Officially launched proprietarily developed botulinum toxin ‘Jeuveau’ (US product name) in the US
Launched ‘Olomax’ which simultaneously targeting high blood pressure and hyperlipidemia
Officially opened ‘Daewoong Pharmaceutical News Room’
‘Nabota’ phase 3 clinical trial results in US was published in SCI-level international academic journal
Investment cooperation with Vietnam’s largest pharmaceutical company ‘Traphaco’
New pulmonary fibrosis drug DWN12088 selected as government-supported project
Hyangnam plant acquired International Safety Health Management System Standard ISO 45001
Internally developed botulinum toxin approved by USFDA, being the first in Asia
Acquired Anti-Corruption Management System ‘ISO 37001’
Quality Circle received Presidential Gold and Silver Award at the ‘National Quality Management Convention’
Nabota acquired the first eye wrinkle indication among domestic botulinum toxin
Quality Circle received the first Grand Prize at the 2018 International Convention on QC Circles (ICQC2018) in the pharmaceutical industry
Established ‘Health Life/Technology Coexistence Fund’
Nabota plant received EU GMP approval
Nabota plant received Canadian GMP approval
Established ‘Daewoong Infion’ bio research center in Indonesia
New drug DWP14012 selected as government-supported project
Nabota plant received cGMP approval in the US
Chairman Yoon Jae-seung, Vice-chairman Lee Jong Wook resigned
Yoon Jae-Chun, Jeon Sengho appointed as CEO to begin professional management system
'Daewoong Infion’ selected as the best bio pharmaceutical company award
Completed Nabota Plant 2 with 4.5 million vials production capability annually
Completed construction of the Osong Plant in Chungbuk with high-tech cGMP facilities
Hyangnam plant re-certified as ‘2017 Gyeonggi Good Work Place Company (GGWP)’
Acquired certification for Outstanding Human Resource Development Institute
Daewoong Pharmaceutical Research Center ‘Daewoong Bio Center’ completed
Prime Minister’s Citation for 'Good Gender Equality Employment Company’
Antibiotic 'Daewoong Meropenem Injection' acquired US FDA approval
Received ‘AA’ rating for two consecutive years from the Fair Trade Commission’s '2016 CP ratings'
Began construction of new plant in Osong, Chungbuk with cGMP levels
Honorary Chairman Yoon Young-hwan received ‘Most Respected Entrepreneur of Korea Award’
Established ‘Ggeumteul Ggeumteul Playground’, an obstacle-free playground at Seoul Children’s Park
Began co-operation with Hanol Bio Pharma
Completed the ‘Daewoong Infion’ bio plant in Indonesia
Received Presidential Award on Fair Trade Day
Olostar received ‘Technology Award’ at the 16th Korean New Drug Awards, New Drug Development Sector
Received CP rating of ‘AA’
Inauguration of Lee Jong Wook as vice-chairman
Received Prime Minister’s Award in science technology at the ‘Korean New Growth Management Awards’
‘Nabota’ selected as world-class product (MOTIE, KOTRA)
Selected for the ‘2014 Gyeonggi Good Work Place Company’ (Gyeonggi Small and Medium Business Center, Gyeonggi-do)
Established ‘Daewoong Pharmaceutical Liaoning Research Institute’ in China
Established Japanese corporation
Inauguration of Yoon Jae-seung as chairman, and Yoon Young-hwan as honorary chairman
Received AA in corporate credit rating
Selected as ‘work-study program’ company (HRD Korea)
Launched botulinum toxin ‘Nabota’ in Korea
Launched new compound Olmesartan-Rosuvastatin drug 'Olostar' in Korea
Received ‘Technology Export Award’ at the Korean Drug Development Awards (Korea Drug Research Association)
Received Prime Minister’s Award for Family-friendly Company
Acquired 2013 Family-friendly Company certification
Received 2013 Innovative Pharmaceutical Company Award
Acquired Chinese pharmaceutical company ‘Baifeng’ to establish Liaoning Daewoong Pharmaceutical
Credit rating predicted to be upgraded to A+Positive
Registered utility model for the ‘Caretropin Pen Injection’ in Russia
Established ‘Daewoong-Infion’ joint-venture in Indonesia
Established corporation in India
‘Caretropin Pen Injection’ received ‘2011-2012 World Star Award’
Selected for the Global Corporate Fostering Project in 'World Class 300'
Selected as 'Innovative Pharmaceutical Company’
Opened the first in-company childcare facility in pharmaceutical industry ‘Little Bear Day Care Center’
Pen injection received Minister of Knowledge and Economy
URSA and Albis received quality certification (GH)
Family-friendly company certification extended to the end of 2013
URSA selected as world-class product
Implemented world’s first herpes labialis treatment with recurrence prevention effects

Daewoong introduced its outstanding R&D capabilities by developing "first-in-class“ and "best-in-class" products

2009 ~ 2000
Next-generation pain killer new drug DWP05195 began clinical trials
Established pharmaceutical research institute in India
Received Prime Minister’s Award at the 'National Productivity Awards’
Established US corporation
Established corporation in Thailand
Acquired outstanding family-friendly company from Ministry of Health, Welfare and Family Affairs
Awarded at National Productivity Awards (leadership, innovation activities sector)
Established obstacle-free playground at the National Assembly‘s day care center
Received appreciation plaque from Yongwol-gun office for the Yongwol ‘1 Company 1 Village' program
Received ‘Korean Association on Smoking and Health Chairman’s Appreciation Plaque’ on No Smoking Day
Easyef received the first international common name certified from WHO
Established corporation in the Philippines
Corporate credit rating upgraded to A+
Selected as outstanding labor-management culture company
Selected as outstanding company for productivity improvement at the Productivity and Innovation Awards
Released Korea’s first 100mg high-content CoQ10
Released high-content vitamin B compound ‘Impactamin Power’
Established branch in China
Minister of Health and Welfare award for family-friendly company
Established obstacle-free playground at Seoul Forest
Lee Jong Wook inaugurated as CEO
Established corporation in Indonesia
'Daewoong Coenzyme Q10' awarded by Minister of Health and Welfare Award at the Health Industry Technology Conference
'Daewoong Coenzyme Q10' received Jang Young-shil Award
Appreciation plaque during parliamentary inspection by the Health and Welfare Committee
Established Vietnam office
Donation to Beautiful Store (Nonhyeon Store)
Daewoong Pharmaceutical Hyangnam Plant acquired ISO14001
Hyangnam Plant acquired International Safety Health Management System certification OHSAS18001
Completed high-tech automated logistics center / implemented APS system
Successfully developed Coenzyme Q10 for the second time in the world
Grand Prize at the Korea Digital Awards
Received Economic Justice Award
Daewoong and Daewoong Pharmaceutical split up
Easyef received KT (New Technology Certification Mark)
Launched world’s first number 1 biotechnology new drug Easyef which is developed in Korea
Hyangnam plant certified as outstanding manufacturing plant (KAIST)

Bold R&D investments and entered of new drug development

1999 ~ 1990
Entered phase 2 for Easyef
Chairman Yoon Young-hwan received Order of Civil Merit, Camellia Medal
Implemented enterprise resource planning (ERP) system
Yoon Jae-seung inaugurated as CEO
Easyef won the Chungmugong Patent Technology Award
Received Minister of Education Award at the Industry-Academic Cooperation Awards
Received Facility Management Award at the National Quality Convention
Received Minister of Education Award at the Industry-Academic Cooperation Awards
Began full operation of the Management Information System
Received Economic Justice Award
Sales exceeded 100 billion KRW
Lee Cheol-bae appointed as honorary chairman
Received Prime Minister’s Award on Labor Day
Completed Hyangnam KGMP plant 2
Prime Minister’s Award at the Industry Promotion Agency Quality Master Awards
Labor Peace Award (Labor and Industriousness Award) from Central Labor Economic Research Institute
Received Outstanding Trademark Award from the Korea Intellectual Property Office
Received Presidential Award by the Ministry of Labor on Labor Day
Received Appreciation Plaque at the 37th General Conference of the Korean Pharmaceutical Association
The first exports, in pharmaceutical industry, to the Soviet Union
Received Korea International Trade Association Chairman Award for increased exports
Received presidential award for the 5 million USD export tower
Received silver medal (indirect sector) Prime Minister’s Award at the National Quality Management Circle Convention

Built foundation for technological partnerships and ventures with foreign companies

1989 ~ 1980
Received gold medal (direct sector) Prime Minister’s Award at the National Quality Management Circle Convention
Received gold medal at the National Quality Management Convention
Developed Pharmaceutical Medical Journal Management Program (PMS)
Moved HQ to Samseong-dong
Received Order of Iron Tower Industry for labor-management sector
Received Order of Iron Tower Industry for science technology sector
Received Minister of Health and Society Award for increased exports of pharmaceutical products
Received presidential award on Science Day (Order of Iron Tower Industry)
Received presidential award for 2 million USD export
Received presidential award on Labor Day Received (Order of Iron Tower Industry)
Received the first genetic engineering patent in Korea
Received Minister of Health and Society Award for export contributions
Designated as KGMP-eligible company
URSA - Designated as official provider for Asian Games and the ‘88 Seoul Olympics
Yoon Young-hwan appointed as chairman, Lee Cheol-bae appointed as president
Received approval to establish central research institute
Completed construction of Daewoong Lilly Plant
Employees began to move-in into new employee apartments
Received Korea Management Awards (education)
Established central research institute
Established Daewoong Lilly Pharmaceutical
Received Order of Gold Tower Industry on Tax Day
Moved HQ to Seocho-dong
Sales exceeded 10 billion KRW

Growth to Korea’s top pharmaceutical company

1979 ~ 1970
Completed production facilities for injection-type antibiotics, opened hospital department
Changed company name to Daewoong Pharmaceutical
Excellence award at the Corporate Public Announcement Conference
Raw materials and technology partnership with Gitse Siraimasu Pharmaceutical of Japan
Began publication of Daewoong Newsletter
Establish Subsidiary Pharmaceutical Research Center
IPO (4th in pharmaceutical industry)
Completed Seongnam plant and moved HQ to Seoul

Daewoong’s dream to build a national company that can contribute to society

1969 ~ 1945
Yoon Young-hwan appointed as CEO
Changed company name to Daehan Vitamin Industries (CEO Park Moon-soo, capital 10 million KRW)
Launched URSA
Moved to new building in Choeup-dong, Busan
Approval for pharmaceutical product manufacturing (Ministry of Health and Society No. 43)
Received Vice President Award at the outstanding domestic product exhibit for the first time in Korea
Founded Joseon Ganyu Pharmaceutical Company